Government-Owned Inventions; Availability for Licensing

Health and Human Services Department; National Institutes of Health · 2011

Read Government-Owned Inventions; Availability for Licensing by Health and Human Services Department; National Institutes of Health (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-17228.txt.

Description

Notice published in the Federal Register on 2011-07-08 by Health and Human Services Department; National Institutes of Health. Text from federalregister.gov (official edition: govinfo). [Pages 40381-40383] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-17228] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions.

Catalog record

CREATORHealth and Human Services Department; National Institutes of Health
YEAR2011
COLLECTIONLAW
FORMATTXT
FILE SIZE17 KB
VERSION1.0
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEFederal Register

Source: https://www.federalregister.gov/documents/2011/07/08/2011-17228/government-owned-inventions-availability-for-licensing

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Government-Owned Inventions; Availability for Licensing Citation: us:fr:2011-17228 Creator: Health and Human Services Department; National Institutes of Health Year: 2011 Source-URL: https://www.federalregister.gov/documents/2011/07/08/2011-17228/government-owned-inventions-availability-for-licensing Context: Notice published in the Federal Register on 2011-07-08 by Health and Human Services Department; National Institutes of Health. Text from federalregister.gov (official edition: govinfo). [Pages 40381-40383] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-17228] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Breakthrough Immunotherapy for Brain Cancer: Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors Description of Technology: Scientists at the National Institutes of Health (NIH) have developed chimeric antigen receptors (CARs) with high affinity for the epidermal growth factor receptor variant III (EGFRvIII) to use as a promising immunotherapy for aggressive brain cancer (glioblastoma) as well as several other malignancies. CARs are hybrid proteins consisting of the portion of an antibody that recognizes a cancer antigen, in this case human monoclonal antibody 139 which recognizes EGFRvIII, fused to protein signaling domains that serve to activate the CAR-expressing cell. Human cells that express CARs, most notably T cells, can recognize specific tumor antigens in an MHC-unrestricted manner with high reactivity and mediate an immune response that promotes robust tumor cell elimination. Advantages EGFRvIII CAR immunotherapy is a breakthrough treatment for glioblastomas, a cancer with no other effective treatment option. EGFRvIII CARs can cross the blood-brain barrier, are expected to target only tumor cells, and thus, generate fewer side effects than other brain cancer treatment approaches. With the advent of Provenge[supreg], personalized immunotherapy is becoming more widely accepted as a viable cancer treatment option. Applications Immunotherapeutics to treat and/or prevent the recurrence of a variety of cancers that overexpress human EGFRvIII, primarily glioblastoma multiforme (GBM). About half of GBM tumor cells express the EGFRvIII antigen. Other cancers that overexpress EGFRvIII include breast, ovarian, prostate, bladder, colorectal, non-small cell lung carcinomas, and head and neck squamous cell carcinomas. A personalized cancer treatment strategy for patients whose tumor cells express EGFRvIII whereby the patient's own T cells are isolated, engineered to express the EGFRvIII specific CAR, and re- infused into the patient to attack the tumor. EGFRvIII is a rare antigen in that is highly expressed by tumor cells, but not expressed by other cells in the body. This cancer antigen is expressed on nearly 50% of GBM tumor cells and also in other tumor types, such as other nervous system cancers and head and neck cancers. There exist very few, if any, effective treatments for GBM, so the expected clinical benefit of an anti-EGFRvIII CAR to patients is expected to be a therapeutic breakthrough for treatment of this cancer. These CARs are expected to combine high affinity recognition of EGFRvIII provided by the antibody portion with the target cell killing activity of cytotoxic T cells. Infusion of these EGFRvIII-specific CARs into patients could prove to be a powerful new immunotherapeutic tool for treating brain cancers, a type of cancer with a long-felt need for breakthrough therapeutics. Development Status: This technology could soon be ready for clinical development. A clinical protocol to utilize an EGFRvIII CAR to treat GBM is currently under review at NIH. Inventors: Richard A. Morgan and Steven A. Rosenberg (NCI). Patent Status: U.S. Provisional Application No. 61/473,409 filed April 8, 2011 (HHS Reference No. E-148-2011/0-US-01). Related Technologies E-269-2010/0--U.S. Provisional Application No. 61/384,931 filed September 21, 2010. E-236-2010/0--U.S. Provisional Application No. 61/405,931 filed October 22, 2010. E-205-2009/0--PCT Application No. PCT/US2010/048701 filed September 14, 2010, which published as WO2011/041093 on April 7, 2011. Relevant Publications 1. Weber R, et al. U.S. Patent No. 7,628,986 issued December 8, 2009 entitled ``Antibodies Directed to the Deletion Mutants of Epidermal Growth Factor Receptor and Uses Thereof''. 2. Carter B.S., et al. U.S. Patent Application No. 12/444,090 filed April 2, 2009 entitled ``Chimeric T-Cell Receptors and T-Cells Targeting EGFRvIII on Tumors''. 3. Bullian SS, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009 Sept;94(3):373- 382. [PMID: 19387557]. 4. Ohno M, et al. Retrovirally engineered T-cell based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 2010 Dec;101(12):2518-2524. [PMID: 20880333]. Licensing Status: Available for licensing. Licensing Contact: Samuel E. Bish, PhD; 301-435-5282; [email protected]. Collaborative Research Opportunity: The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize cell-based immunotherapies targeting EGFRvIII expressing cancers. Please contact John Hewes, PhD at 301-435- 3121 or [email protected] for more information. An Improved Anti-Mesothelin Immunotoxin for Treatment of Mesothelioma, Lung Cancer, Ovarian Cancer and Pancreatic Cancer Description of Technology: Mesothelin is a cell surface glycoprotein that is highly expressed in many cancers (e.g., malignant mesothelioma, lung cancer, ovarian cancer, and pancreatic cancer). Because of its differential expression, mesothelin is an excellent [[Page 40382]] target for the selective killing of cancer cells. For instance, anti- mesothelin monoclonal antibodies can carry cellular toxins specifically to mesothelin-expressing cancer cells, resulting in their selective killing while healthy, essential cells remain unharmed. A high affinity anti-mesothelin antibody (SS1) was previously combined with a functional fragment of Pseudomonas Exotoxin A (PE), producing the immunotoxin SS1P. SS1P selectively killed mesothelin- expressing cancer cells, suggesting it could be an excellent therapeutic agent. Unfortunately, PE-based immunotoxins can lose therapeutic efficacy following multiple administrations, due to the formation of neutralizing antibodies against the PE portion of the molecule. As a result, less immunogenic variants of PE have been created in order to develop immunotoxins that do not induce the formation of neutralizing antibodies. Improved PE variants have been created which lack lysosomal protease sites, a dominant T-cell epitope (PE-LR), and several major B- cell epitopes (PE-LR/8M). Although these new PE variants demonstrate efficient cell killing activity when used in combination with certain antibodies, their activity when using SS1 as the targeting agent (SS1- LR and SS1-LR/8M) was less impressive. Fortunately, the inventors surprisingly discovered that the addition of a small linker peptide within these immunotoxins was able to restore their cell killing activity to the level of SS1P. These new SS1-targeted immunotoxins (e.g., SS1-LR/GGS and SS1-LR/ GGS/8M) have the cell-killing activity of SS1P, but are less likely to generate neutralizing antibodies. As a result, these immunotoxins are considered to be very promising prospects for treating patients suffering from mesothelin-expressing cancers. Applications Treatment of mesothelin expressing cancers, including mesothelioma, pancreatic cancer, ovarian cancer and lung adenocarcinoma. Treatment

Read the complete text